Natco Pharma Limited

Type: Company
Name: Natco Pharma Limited (NATCO Pharma Limited)
First reported 5 hours ago - Updated 5 hours ago - 1 reports

India: The silver lining in India’s latest CL decision

In its recent judgment, the Bombay High Court dismissed Bayer's appeal against the grant of a compulsory license (CL) to Natco, a generic manufacturer, for its Indian patent on an anti-cancer drug called Nexavar. This order of the Bombay High Court is ... [Published Managing IP - 5 hours ago]
First reported 8 hours ago - Updated 8 hours ago - 1 reports

Market close at record highs; nearly 300 stocks hit 52-week high on BSE

NEW DELHI: The S&P BSE Sensex rallied as much as 262 points in trade on Monday, to hit its fresh lifetime high of 26,900.30, led by gains in Cipla, DRL, HUL, M&M, Hero MotoCorp, ICICI Bank, Maruti Suzuki and Tata Motors which also rallied to their fresh ... [Published Economic Times - 8 hours ago]
First reported 9 hours ago - Updated 9 hours ago - 1 reports

Nifty ends above 8,000 for the first time on GDP data

Benchmark share indices ended at record closing highs with the Nifty breaching the psychological 8,000 level for the first time after better-than-expected first quarter GDP data fuelled a rally led by capital goods and bank shares.The 30-share Sensex ... [Published Business Standard India - 9 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 2 reports

Midcap-Monitor: Natco Pharma, Unitech among top gainers

Even though the benchmark indices are trading at record highs the broader markets have outperformed as investors are now seen bargain hunting in the mid-cap and small-cap segments.The broader markets hit record highs after better-than-expected GDP growth ... [Published Smart Investor - 11 hours ago]
First reported 15 hours ago - Updated 12 hours ago - 7 reports

Natco's US marketing partner files ANDA for 'Copaxone'

Natco Pharma's marketing partner in the USA, Mylan Inc., has filed an Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE (glatiramer acetate injection, 40 mg/mL) and has been accepted by the US Food and Drug Administration ... [Published Indian-Commodity - 12 hours ago]
First reported 16 hours ago - Updated 16 hours ago - 1 reports

Here are top 10 stocks to keep an eye on Sep 1

- Sun TV, Spicejet, JSPL, Hindalco, Coal India, Cipla, Wockhardt, Natco Pharma, Bharti Airtel and Bajaj Electricals. ... [Published Moneycontrol.com - 16 hours ago]
First reported Aug 30 2014 - Updated Aug 30 2014 - 2 reports

Natco Pharma’s partner Mylan files for Copaxone generic

An Abbreviated New Drug Application (ANDA) for three-times-a-week generic Copaxone (glatiramer acetate injection) filed by Mylan Inc has been accepted by the US Food and Drug Administration (US FDA).According to a released issued by Natco Pharma Ltd here ... [Published Hindu Business Line - Aug 30 2014]
First reported Aug 30 2014 - Updated Aug 30 2014 - 1 reports

Natco gets USFDA approval for generic Copaxone

Hyderabad-based Natco Pharma said that USFDA has accepted the abbreviated new drug application (ANDA) for generic Copaxone filed by its marketing partner in the US, Mylan.Copaxone is indicated for the treatment of patients with relapsing forms of multiple ... [Published Business Standard India - Aug 30 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

No biosimilars rollout for the next five years

Even as Indian drugmakers are looking at biosimilars as the next big thing, it may take a few years before it kicks off as a mainstream revenue segment, given challenges like huge investments and regulatory hurdles in developed economies.Existing players ... [Published Financial Chronicle - Aug 28 2014]
First reported Aug 26 2014 - Updated Aug 27 2014 - 2 reports

Natco Pharma Ltd appoints Additional Directors

Exim Bank has with drawn their Nominee Director from the Board of Directors of Natco Pharma Ltd and the Board of Directors by way Resolution by circulation appointed Mr. T V Rao as Additional Directors of the Company.Dr. Mrs. Leela Digumarti, appointed ... [Published Equity Bulls - Aug 27 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Pharma shares on a roll on strong growth prospects

Shares of pharmaceutical companies continued their upward march with most of the frontline stocks are trading at their lifetime highs after reporting healthy results for the June quarter. Analysts believe that the the Indian pharma market is likely to ... [Published Business Standard India - Aug 26 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 3 reports

Natco Pharma Q1 profit jumps 54% to Rs33.46 crore

Natco Pharma has at least half a dozen specialty generic drugs in the domestic market. Photo: AFPMumbai: Hyderabad-based cancer drug maker Natco Pharma Ltd. on Tuesday said it posted a 54% increase in net profit at Rs33.46 crore during the April-June ... [Published Livemint.com - Aug 12 2014]

Quotes

...In pertinent part, this provision stated that patents "are not granted merely to enable patentees to enjoy a monopoly for the importation of the patented article" . The Bombay High Court interpreted this provision in the context of the other principles under Section 83, to reach its conclusion that the issue of...
"Marketing partner in the USA, Mylan Inc has filed an abbreviated new drug application (ANDA) for a three-times-a-week generic Copaxone (glatiramer acetate injection, 40 mg/ml) and has been accepted by the US FoodFood and Drug Administration (USFDA)" said the company in its filing
` "`It expects to be eligible for 180 days of marketing exclusivity in the U S upon final FDA approval,’’ the Hyderabad-based company said."
"Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of market exclusivity in the US upon final FDA approval" Natco Pharma said

More Content

All (85) | News (70) | Reports (0) | Blogs (14) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
India: The silver lining in India’s latest CL d... [Published Managing IP - 5 hours ago]
Market close at record highs; nearly 300 stocks... [Published Economic Times - 8 hours ago]
Nifty ends above 8,000 for the first time on GD... [Published Business Standard India - 9 hours ago]
Midcap-Monitor: Natco Pharma, Unitech among top... [Published Smart Investor - 11 hours ago]
Midcap-Monitor: Natco Pharma, Unitech among top... [Published Business Standard India - 11 hours ago]
Natco's US marketing partner files ANDA for 'Co... [Published Indian-Commodity - 12 hours ago]
Natco Pharma gains 5%; hits 52-week high [Published Business Standard India - 12 hours ago]
See shared exclusivity on Copaxone generic 40mg... [Published Moneycontrol.com - 13 hours ago]
Natco Pharma hits record high [Published Capital Market - 14 hours ago]
Natco Pharma at record high; partner Mylan file... [Published Moneycontrol.com - 14 hours ago]
Natco jumps after Mylan files ANDA for Copaxone [Published MyIris - 14 hours ago]
Natco Pharma`s partner Mylan files ANDA for Cop... [Published MyIris - 15 hours ago]
Here are top 10 stocks to keep an eye on Sep 1 [Published Moneycontrol.com - 16 hours ago]
Natco Pharma’s partner Mylan files for Copaxone... [Published Hindu Business Line - Aug 30 2014]
Natco's partner Mylan Inc files ANDA for generi... [Published Business Standard India - Aug 30 2014]
NATCO's marketing partner, Mylan Inc., files AN... [Published Noodls - Aug 30 2014]
Natco gets USFDA approval for generic Copaxone [Published Business Standard India - Aug 30 2014]
No biosimilars rollout for the next five years [Published Financial Chronicle - Aug 28 2014]
Stocks in news: ONGC, Adani Power, Torrent Phar... [Published Moneycontrol.com - Aug 28 2014]
Natco Pharma Ltd appoints Additional Directors [Published Equity Bulls - Aug 27 2014]
Natco Pharma announces change in directorate [Published HDFC Securities - Aug 26 2014]
Pharma shares on a roll on strong growth prospects [Published Business Standard India - Aug 26 2014]
Bombay HC upholds India’s first Compulsory License [Published Lexology - Aug 22 2014]
GRANTING CL FOR DASATINIB [Published PharmaBiz - Aug 20 2014]
3 Reasons Mylan Inc Stock Could Rise [Published Motley Fool - Aug 19 2014]
Indian Health Ministry seeking compulsory licen... [Published Pharma Letter - Aug 19 2014]
Pharma Patent Ruling Pinches Opportunities in E... [Published AdvisorOne - Aug 19 2014]
Cancer Genetics Inc completes BioServe India buy [Published Economic Times - Aug 18 2014]
Cancer Genetics Inc. Completes Acquisition of B... [Published EMoneyDaily - Aug 18 2014]
Net sales rise at fastest pace in nine quarters... [Published BusinessWeek - Aug 16 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Court Report [Published Patent Docs - Jun 01 2014]
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Cephalon Inc. v. Breckenridge Pharmaceutical Inc. et al. 1:14-cv-00671; filed May 27, 2014 in the District Court of Delaware•Plaintiff: ...
6 Drugs That Could Move the Market [Published Wall St. Cheat Sheet - Apr 29 2014]
Overview In the last few years, a number of promising drugs that treat serious conditions and diseases have come through drugmakers’ pipelines. Recent developments in oncology, for instance, mean that there are more promising, potential blockbuster ...
Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed... [Published Patent Docs - Apr 29 2014]
By Kevin E. Noonan -- The Federal Circuit extended the scope of the judicially created doctrine of obviousness-type double patenting (OTDP) in a split decision rendered in Gilead Sciences Inc. v. Natco Pharma Ltd. In doing so, the panel majority applied ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published EON Business - Apr 25 2014]
HARTFORD, Conn.--(EON: Enhanced Online News)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular ...
Federal Circuit Rules for Axinn Client Natco Ph... [Published Business Wire Professional Services News - Apr 25 2014]
HARTFORD, Conn.--(BUSINESS WIRE)--A ruling by the U.S. Court of Appeals for the Federal Circuit has given Axinn, Veltrop & Harkrider LLP client Natco Pharma Ltd. a second chance at invalidating Gilead Sciences Inc.’s patent on the popular flu drug Tamiflu. ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.